Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285584997> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4285584997 endingPage "29" @default.
- W4285584997 startingPage "25" @default.
- W4285584997 abstract "Objective:To compare the efficacy of Gemcitabine and Mitomycin C in the treatment of non muscle invasive transitional cell carcinoma of urinary bladder.
 Methods: This study was a randomized clinical trial conducted between the periods of November’2013 to October’2014 in the Department of Urology, Bangabandhu Sheikh Mujib Medical University (BSMMU) The patients with histopathologicaly diagnosed as non muscle invasive transitional cell carcinoma of urinary bladder after complete TURBT were included in the study. Total 54 patients were included in this study ( 27 patients in each group). Those treated with intravesical Gemcitabine were considered as experimental group and those treated with intravesical Mitomycin C (MMC) considered as control group. Intravesical Inj. Gemcitabine and Mitomycin C mg dissolved in 50 ml of normal saline and instilled into the urinary bladder through Foley urethral catheter in the considered group and kept for two hour after getting the histopathology report. Same schedule was maintained weekly for 6 weeks. All patients were followed up at 6 weeks after 1st cycle of intravesical instillation then 3 monthly for 1 year.
 Result : Presence of recurrence of tumour was found non-significant in Gemcitabine and Mitomycin C group (18.5% vs. 40.7%, p= 0.074). Recurrence free survival was found 81.5% patients in Gemcitabine group and that of 59.3% patients in Mitomycin group. Though there was more recurrence free survival in gemcitabine group than mitomycin group, there was no statistically significant difference. Tumour grade progression was found in 20% and 27.3% cases in Gemcitabine and Mitomycin C group respectively. On the other hand, tumour stage progression was found 40.0% and 27.3% patients in Gemcitabine and Mitomycin C group respectively. No statistically significant difference was observed between Groups (P>0.05). Haematuria, dysuria, urinary frequency, urgency and contact dermatitis were found non-statistically significant in both groups.
 Conclusion : Gemcitabine and Mitomycin C both drugs are effective as intravesical chemotherapy in the treatment of non muscle invasive transitional cell carcinoma of urinary bladder and have a better recurrence free survival. But, accounting statistical significance on chemopreventive activity, neither Gemcitabine nor Mitomycin C therapy showed superiority over each other.
 Bangladesh Journal of Urology, Vol. 22, No. 1, January 2019 p.25-29" @default.
- W4285584997 created "2022-07-16" @default.
- W4285584997 creator A5019233359 @default.
- W4285584997 creator A5032660516 @default.
- W4285584997 creator A5061308270 @default.
- W4285584997 creator A5065579684 @default.
- W4285584997 creator A5080047125 @default.
- W4285584997 creator A5082004256 @default.
- W4285584997 date "2020-11-02" @default.
- W4285584997 modified "2023-09-27" @default.
- W4285584997 title "Intravesical Gemcitabine and Mitomycin C Chemotherapy in the Treatment of Non Muscle Invasive Transitional Cell Carcinoma of Urinary Bladder - a Randommized Clinical Trial" @default.
- W4285584997 doi "https://doi.org/10.3329/bju.v22i1.50071" @default.
- W4285584997 hasPublicationYear "2020" @default.
- W4285584997 type Work @default.
- W4285584997 citedByCount "2" @default.
- W4285584997 countsByYear W42855849972023 @default.
- W4285584997 crossrefType "journal-article" @default.
- W4285584997 hasAuthorship W4285584997A5019233359 @default.
- W4285584997 hasAuthorship W4285584997A5032660516 @default.
- W4285584997 hasAuthorship W4285584997A5061308270 @default.
- W4285584997 hasAuthorship W4285584997A5065579684 @default.
- W4285584997 hasAuthorship W4285584997A5080047125 @default.
- W4285584997 hasAuthorship W4285584997A5082004256 @default.
- W4285584997 hasBestOaLocation W42855849971 @default.
- W4285584997 hasConcept C121608353 @default.
- W4285584997 hasConcept C126322002 @default.
- W4285584997 hasConcept C126894567 @default.
- W4285584997 hasConcept C141071460 @default.
- W4285584997 hasConcept C2776694085 @default.
- W4285584997 hasConcept C2778065480 @default.
- W4285584997 hasConcept C2779338040 @default.
- W4285584997 hasConcept C2779762690 @default.
- W4285584997 hasConcept C2780258809 @default.
- W4285584997 hasConcept C2780352672 @default.
- W4285584997 hasConcept C71924100 @default.
- W4285584997 hasConceptScore W4285584997C121608353 @default.
- W4285584997 hasConceptScore W4285584997C126322002 @default.
- W4285584997 hasConceptScore W4285584997C126894567 @default.
- W4285584997 hasConceptScore W4285584997C141071460 @default.
- W4285584997 hasConceptScore W4285584997C2776694085 @default.
- W4285584997 hasConceptScore W4285584997C2778065480 @default.
- W4285584997 hasConceptScore W4285584997C2779338040 @default.
- W4285584997 hasConceptScore W4285584997C2779762690 @default.
- W4285584997 hasConceptScore W4285584997C2780258809 @default.
- W4285584997 hasConceptScore W4285584997C2780352672 @default.
- W4285584997 hasConceptScore W4285584997C71924100 @default.
- W4285584997 hasIssue "1" @default.
- W4285584997 hasLocation W42855849971 @default.
- W4285584997 hasOpenAccess W4285584997 @default.
- W4285584997 hasPrimaryLocation W42855849971 @default.
- W4285584997 hasRelatedWork W2043283767 @default.
- W4285584997 hasRelatedWork W2147140925 @default.
- W4285584997 hasRelatedWork W2214729802 @default.
- W4285584997 hasRelatedWork W2387922007 @default.
- W4285584997 hasRelatedWork W2429664059 @default.
- W4285584997 hasRelatedWork W3093290564 @default.
- W4285584997 hasRelatedWork W4285584997 @default.
- W4285584997 hasRelatedWork W4303057512 @default.
- W4285584997 hasRelatedWork W4313197990 @default.
- W4285584997 hasRelatedWork W2118673085 @default.
- W4285584997 hasVolume "22" @default.
- W4285584997 isParatext "false" @default.
- W4285584997 isRetracted "false" @default.
- W4285584997 workType "article" @default.